crossing96/oncoscreening huggingface dataset:
Unveiling ADAMTS12: A key driver of bladder cancer progression via COL3A1-Mediated activation of the FAK/PI3K/AKT signaling pathway.	Bladder cancer (BCa) is a common and lethal disease characterized by high recurrence rates and limited treatment options. Understanding the molecular pathways of BCa progress is crucial for investigating more effective targeted therapies. While ADAMTS12 is known to contribute to cancer progression and treatment resistance, its prognostic significance and underlying mechanisms in BCa remain poorly understood. To elucidate the molecular pathways and functions of ADAMTS12 in BCa, we employed various experimental approaches, including Transwell invasion assays, flow cytometry analysis, wound-healing assays, CCK-8 assays, and a xenograft tumor model. Our results demonstrated that overexpression of ADAMTS12 significantly enhanced cell growth, migration, and invasion while inhibiting apoptosis through the activation of the FAK/PI3K/AKT signaling pathway. Conversely, the knockdown of ADAMTS12 produced the opposite effects. In vivo studies further confirmed that the inhibition of ADAMTS12 effectively suppressed tumor progression. Comprehensive bioinformatics analysis of the TCGA-BLCA dataset and protein-protein interaction networks revealed a strong positive correlation between COL3A1 and ADAMTS12, identifying COL3A1 as a potential downstream target of ADAMTS12. Additionally, we observed a significant increase in the expression levels of ADAMTS12 and COL3A1 in BCa tissues compared to healthy tissues, as confirmed by Western blotting and qRT-PCR analysis. Notably, inhibition of COL3A1 reversed the enhanced cell growth and invasion associated with ADAMTS12 overexpression and suppressed cell apoptosis. Our findings suggest that ADAMTS12 promotes BCa progression through the FAK/PI3K/AKT signaling pathway by regulating COL3A1, highlighting its potential as a valuable marker for diagnosis and prognosis in BCa.	bladder
Microfilaria in the Urine of a Dog with Concurrent Urinary Bladder Sarcoma.	A 12 yr old female spayed American Staffordshire terrier was referred for stranguria, pollakiuria, and concern for a mass in the trigone of the urinary bladder. A urinalysis and abdominal ultrasound were performed to further investigate the bladder mass. Nematode larvae were identified in the urine, termed microfilaruria, while a caudal abdominal mass was found on ultrasound impinging on the urethra. Fine-needle aspirate of the abdominal mass revealed malignant neoplasia. A SNAP 4Dx of the peripheral blood was positive for Dirofilaria immitis antigen and a modified Knott's test confirmed D immitis larvae. The patient was euthanized owing to poor prognosis, and multiple masses were found within the abdominal cavity that, based on histopathology and immunohistochemistry, were diagnosed as poorly differentiated sarcoma. Hemorrhage, secondary to the abdominal mass, was considered the primary cause of microfilaruria.	bladder
Assessment of Prostate MR Image and Predictive Value for Benign Prostate Disease among Different DWI Sequences.	BACKGROUND: Early diagnosis of prostate cancer can improve the survival rate of patients on the premise of high-quality images. The prerequisite for early diagnosis is high-quality images. ZOOMit is a method for high-resolution, zoomed FOV imaging, allowing diffusion-weighted images with high contrast and resolution in short acquisition times. RESOLVE DWI is an advanced MRI technique developed to obtain high-resolution diffusionweighted images with reduced susceptibility-related artifacts. OBJECTIVE: This study aimed to compare the image quality of conventional single-shot Echo-planar Imaging (ss-EPI), Diffusion-weighted Imaging (DWI), zoomed FOV imaging (ZOOMit) DWI, and readout segmentation of long variable echo-trains (RESOLVE) DWI sequences for prostate imaging, and optimize the strategy to obtain high-quality Magnetic Resonance Imaging (MRI) in order to discriminate malignant and benign prostate diseases. METHODS: Fifty-one patients were enrolled, including 31 with prostate cancer, 11 with prostate benign disease, and 9 with bladder cancer. Patients underwent MRI scans using T2-weighted (T2W), ss-EPI DWI, ZOOMit DWI, and RESOLVE DWI (b = 0, 50, 1400 s/mm2) sequences using a 3.0T MRI scanner. Subjective scores of image quality were evaluated by two independent radiologists. Differences in the subjective scores and objective parameters among the three sequences were compared. The agreement and consistency between the findings of the two raters were evaluated with Kappa or Intra-class Correlation Coefficient (ICC). Receiver Operating Characteristic (ROC) curves were used to distinguish malignant and benign prostate disease. RESULTS: The agreement of subjective scores of 51 patients was high or moderate between the two radiologists (kappa: 0.529-0.880). ZOOMit displayed the highest clarity and the lowest distortion and artifacts compared to ss-EPI and RESOLVE. The two radiologic technicians obtained moderate or high consistency of objective measurement (ICC: 0.527-0.924). In the ROC analysis, ADCmean and Prostate Imaging Reporting and Data System (PI-RADS) scores for three sequences were comparable in differentiating prostate cancer from benign prostate disease (all p>0.05), in which ZOOMit indicated the highest Area Under the Curve (AUC) (0.930 and 0.790, respectively). CONCLUSION: Compared to the other two sequences, ZOOMit can be deemed preferable to improve prostate MRI diffusion imaging as it has exhibited the highest AUC in identifying prostate cancer.	bladder
Bowel regimens before radical cystectomy: An analysis of a modern cohort.	INTRODUCTION: Bowel regimens (BR) before radical cystectomy (RC) are currently not recommended by Enhanced Recovery After Surgery (ERAS) protocols, as prior studies have shown BRs lead to worsened outcomes. However, many of those studies have used historic literature before recent surgical advancements such as minimally invasive RC and have not investigated the impact BRs have by type of urinary diversion. Our goal is to determine the outcomes of preoperative BR in patients undergoing RC based on diversion type using a modern patient cohort. METHODS: RCs performed between 2019 and 2020 with BR information available were identified in the American College of Surgeons' National Surgical Quality Improvement Program (NSQIP). Patients were grouped by type of BR received: no BR, both mechanical bowel preparation (MBP) and preoperative oral antibiotic BR (OABR), MBP only, and OABR only. We conducted propensity score matching based on factors influencing the operative approach. Baseline demographics and 30-day complication rates were compared between matched groups. We analyzed hospital length of stay (LOS) via multivariate regression with a Poisson distribution. RESULTS: In total, 2054 RCs were identified with 2.4% receiving OABR, 21.3% receiving MBP, 5.3% receiving both, and 71.0% receiving no BR. For patients with ileal conduit diversions, outcomes with BRs appeared mixed, as OABR leads to increased LOS. For patients with neobladder diversions, BRs were not associated with any worsened outcomes and were associated with reduced length of stay. CONCLUSIONS: BRs such as OABR may associated with improved outcomes in patients receiving RC with neobladder diversion, a finding that warrants further investigation.	bladder
Comprehensive genomic characterization of early-stage bladder cancer.	Understanding the molecular landscape of nonmuscle-invasive bladder cancer (NMIBC) is essential to improve risk assessment and treatment regimens. We performed a comprehensive genomic analysis of patients with NMIBC using whole-exome sequencing (n = 438), shallow whole-genome sequencing (n = 362) and total RNA sequencing (n = 414). A large genomic variation within NMIBC was observed and correlated with different molecular subtypes. Frequent loss of heterozygosity in FGFR3 and 17p (affecting TP53) was found in tumors with mutations in FGFR3 and TP53, respectively. Whole-genome doubling (WGD) was observed in 15% of the tumors and was associated with worse outcomes. Tumors with WGD were genomically unstable, with alterations in cell-cycle-related genes and an altered immune composition. Finally, integrative clustering of multi-omics data highlighted the important role of genomic instability and immune cell exhaustion in disease aggressiveness. These findings advance our understanding of genomic differences associated with disease aggressiveness in NMIBC and may ultimately improve patient stratification.	bladder
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.	PURPOSE: Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guérin (BCG) treatment, resulting in a high risk of progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects of BCG are driven by a cytotoxic T cell response, which may be controlled by immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1). Here, we hypothesized that PD-L1 protein expression could serve as a biomarker for BCG-failure. METHODS: HR-NMIBC patients who received ≥ 5 BCG instillations were included. Tissue microarrays were constructed from BCG-naïve tumors and recurrences and stained with the PD-L1 (SP142) antibody. PD-L1 status was defined as ≥ 5% tumor-infiltrating immune cells with membrane staining in the tumor area. Clinicopathological associations with PD-L1 positive tumors were investigated, and time-to-event analyses were performed comparing PD-L1 positive vs. negative tumors. RESULTS: 432 BCG-naïve tumors and 160 recurrences were included, and 91% of patients received adequate BCG. In BCG-naïve tumors, PD-L1 was expressed in 7% of patients and PD-L1 expression was associated with stage T1 versus Ta disease (p = 0.015). PD-L1 expression was not associated with treatment failure after adequate BCG (p = 0.782) nor with progression-free survival (p = 0.732). Testing cut-offs of ≥ 1% and ≥ 10% PD-L1 positivity did not alter results. High PD-L1 expression was more frequent in tumor recurrences (14%) as compared to BCG-naïve tumors (p = 0.012). CONCLUSION: PD-L1 expression in HR-NMIBC is not a biomarker of response to BCG. However, PD-L1 is higher in a subset of tumors that failed BCG treatment. More research is needed to determine the role of PD-L1 in tumors where BCG treatment failed.	bladder
Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis.	BACKGROUND: The prognostic value of C-reactive protein (CRP) in patients with bladder cancer (BCa) has been widely analysed; however, the results remain conflicting. Therefore, we performed this meta-analysis to identify the precise role of CRP level in predicting BCa prognosis. METHODS: PubMed, Web of Science, Embase and Cochrane Library databases were comprehensively searched until 19 April 2024. The impact of CRP level on predicting the prognosis of patients with BCa was examined using combined hazard ratios (HRs) and 95% confidence intervals (CIs). The relationship between CRP level and BCa clinicopathological characteristics was investigated by combining the odds ratios (ORs) with 95%CIs. RESULTS: Twenty studies with 7276 patients were enrolled in this study. As revealed by pooled data, elevated CRP levels were markedly related to poor overall survival (OS) (HR = 2.02, 95%CI = 1.41-2.90, p < .001), inferior cancer-specific survival (CSS) (HR = 1.46, 95%CI = 1.29-1.66, p < .001), shortened recurrence-free survival (RFS) (HR = 1.25, 95%CI = 1.17-1.33, p < .001) and dismal progression-free survival (PFS) (HR = 2.28, 95%CI = 1.80-2.90, p < .001) in BCa patients. Nevertheless, there was no significant relationship between CRP level and sex, tumour size, tumour grade or lymph node metastasis (LNM) in BCa. CONCLUSIONS: Elevated CRP levels were significantly related to poor OS, CSS, RFS and PFS of BCa patients with BCa. CRP could act as a reliable biomarker for predicting the short- and long-term survival of patients with BCa in clinical practice.	bladder
Stage at diagnosis and cancer-specific survival for stomach, lung, colorectal, and bladder cancers among Armenians in California.	OBJECTIVE: To observe stage at diagnosis and cancer-specific survival for common cancers among Armenians in California. METHODS: We used the Armenian Surname List and birthplace information in the California Cancer Registry to identify Armenians with stomach, lung, colorectal, and bladder cancers diagnosed during 1988-2019. We used multivariable logistic regression models to calculate odds of late-stage diagnoses among Armenian and non-Armenian, non-Hispanic White patients and examine the association of sociodemographic factors with late-stage diagnoses among the Armenian patient population. We used Cox proportional hazards models to calculate cancer-specific survival among Armenian patients compared to non-Armenian, non-Hispanic White patients. RESULTS: Of the 639,224 cancer diagnoses identified, 6642 were among Armenian patients. Armenian individuals were more likely to be diagnosed with late-stage colorectal (OR = 1.12, 95 % CI = 1.03-1.22), lung (OR = 1.26, 95 % CI = 1.12-1.42), and stomach (OR = 1.43, 95 % CI = 1.17-1.74) cancers. Among Armenian patients, low nSES and public insurance were associated with late-stage diagnoses. Armenian individuals had better survival than non-Armenian, non-Hispanic White individuals for stomach (HR = 0.85, 95 % CI = 0.76-0.94), lung (HR = 0.86, 95 % CI = 0.82-0.91), colorectal (HR = 0.82, 95 % CI = 0.77-0.88), and bladder (HR = 0.87, 95 % CI = 0.76-0.99) cancers. CONCLUSION: While Armenian patients were at greater risk of late-stage diagnoses of colorectal, lung, and stomach cancers, they had better survival compared to non-Armenian, non-Hispanic White patients. Further research is needed to understand factors impacting survival in Armenian individuals, including genetic, behavioral, and social factors. Our findings of lower nSES and public health insurance associated with late-stage diagnoses suggest a need for increased access to care and cancer screening among the Armenian population in California.	bladder
Exploring the potential of the combined diagnostic model of ADC value and bp-MRI VI-RADS in the evaluation of muscle invasion in bladder Cancer.	OBJECTIVE: This study investigates the diagnostic value of Vesical Imaging Reporting and Data System (VI-RADS) in biparametric MRI (bp-MRI) for the detection of muscular infiltration in bladder cancer, and to investigate whether apparent diffusion coefficient (ADC) value can function as a potential indicator of bp-MRI VI-RADS for patient benefit. MATERIALS AND METHODS: This single-center retrospective study enrolled 81 patients with pathologically confirmed bladder cancer from October 2019 to November 2021. Two readers independently scored the T2-weighted images and diffusion-weighted images of each index lesion based on the VI-RADS criteria, subsequently deriving the bp-MRI VI-RADS scores. Both ADC values and bp-MRI VI-RADS scores were utilized to develop a simple model by logistic regression. Receiver-operating characteristic curve assessed all systems, while decision curve analysis (DCA) and calibration curves evaluated the model's performance. RESULTS: The area under the curve (AUC) of bp-MRI VI-RADS was 0.886 (95% confidence interval [CI]: 0.801-0.971), with the diagnostic accuracy, sensitivity, and specificity being 0.753, 0.962, and 0.655 respectively. Regarding the ADC value, its AUC was 0.899 (95% CI: 0.821-0.977), and the diagnostic accuracy, sensitivity, and specificity were 0.877, 0.846, and 0.891. The AUC of the simple combined model achieved 0.942 (95% CI: 0.881-0.999), and the diagnostic accuracy, sensitivity, and specificity were 0.889, 0.885, and 0.891. The DeLong test verified that there was a statistically significant difference in AUC between the model and bp-MRI VI-RADS alone (P < 0.05). The simple model demonstrated excellent clinical applicability via DCA and calibration plots. CONCLUSIONS: The contrast-free bp-MRI VI-RADS demonstrates commendable diagnostic efficacy for diagnosing muscular infiltration in bladder cancer. Additionally, ADC values can complement bp-MRI VI-RADS, enhancing diagnostic performance.	bladder
Identification and validation of the nicotine metabolism-related signature of bladder cancer by bioinformatics and machine learning.	BACKGROUND: Several studies indicate that smoking is one of the major risk factors for bladder cancer. Nicotine and its metabolites, the main components of tobacco, have been found to be strongly linked to the occurrence and progression of bladder cancer. However, the function of nicotine metabolism-related genes (NRGs) in bladder urothelial carcinoma (BLCA) are still unclear. METHODS: NRGs were collected from MSigDB to identify the clusters associated with nicotine metabolism. Prognostic differentially expressed genes (DEGs) were filtered via differentially expression analysis and univariate Cox regression analysis. Integrative machine learning combination based on 10 machine learning algorithms was used for the construction of robust signature. Subsequently, the clinical application of signature in terms of prognosis, tumor microenvironment (TME) as well as immunotherapy was comprehensively evaluated. Finally, the biology function of the signature gene was further verified via CCK-8, transwell migration and colony formation. RESULTS: Three clusters associated with nicotine metabolism were discovered with distinct prognosis and immunological patterns. A four gene-signature was developed by random survival forest (RSF) method with highest average Harrell's concordance index (C-index) of 0.763. The signature exhibited a reliable and accurate performance in prognostic prediction across TCGA-train, TCGA-test and GSE32894 cohorts. Furthermore, the signature showed highly correlation with clinical characteristics, TME and immunotherapy responses. Suppression of MKRN1 was found to reduce the migration and proliferation of bladder cancer cell. In addition, enhanced migration and proliferation caused by nicotine was blocked down by loss of MKRN1. CONCLUSIONS: The novel nicotine metabolism-related signature may provide valuable insights into clinical prognosis and potential benefits of immunotherapy in bladder cancer patients.	bladder
Loss of YTHDC1 m(6)A reading function promotes invasiveness in urothelial carcinoma of the bladder.	Bladder cancer poses significant clinical challenges due to its high metastatic potential and poor prognosis, especially when it progresses to muscle-invasive stages. Here, we show that the m(6)A reader YTHDC1 is downregulated in muscle-invasive bladder cancer and is negatively correlated with the expression of epithelial‒mesenchymal transition genes. The functional inhibition or depletion of YTHDC1 increased the migration and invasion of urothelial cells. Integrative analysis of multimodal sequencing datasets provided detailed insights into the molecular mechanisms mediating YTHDC1-dependent phenotypes and identified SMAD6 as a key transcript involved in the invasiveness of urothelial carcinoma of the bladder. Notably, SMAD6 mRNA colocalized less with YTHDC1 in tumoral tissues than in paratumoral tissues, indicating disrupted binding during cancer progression. Our findings establish YTHDC1-dependent m(6)A reading as a critical epitranscriptomic mechanism regulating bladder cancer invasiveness and provide a paradigm for the epitranscriptomic deregulation of cancer-associated networks.	bladder
Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer.	OBJECTIVE: The intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) prognostic group is heterogeneous. Growing evidence supports the role of active surveillance (AS) for patients with low-risk NMIBC, however, no clear data exists considering IR-NMIBC. The aim of the study was to assess the risk of recurrence of patients eligible for AS based on the International Bladder Cancer Group (IBCG) stratification. METHODS: We retrospectively evaluated 174 LG IR-NMIBC patients who underwent transurethral resection of bladder tumor (index TURBT) from 2012 to 2023 at a tertiary referral center and fulfilled the inclusion criteria for enrollment in AS protocols at the index TURBT (≤ 5 suspicious lesions, no macrohematuria, negative urine cytology, lesions ≤ 1 cm). Patients were then stratified according to the International Bladder Cancer Group (IBCG) risk factors: frequent recurrence, early recurrence, previous instillation, and multifocality. Kaplan Meier plots and multivariable Cox regression analysis (MVA) were used to assess the risk of any and high-grade (HG) recurrence according to the number of risk factors. RESULTS: Overall, 168 (97%) patients had a Ta low grade bladder tumor. After a median follow-up of 36 months [Interquartile range (IQR) 20-54], 75 (43%) and 32 (18%) patients experienced any- and HG recurrence, respectively. The 3-year recurrence free-survival (RFS) was 86% [95% Confidence Interval (CI) 76-98%] for patients with 0, 76% (95% CI 68-84%) for those with 1-2, and 54% (95% CI 34-84%) for those with ≥ 3 risk factors. The 3-year HG-RFS was > 90% for patients with 0 and 1-2 risk factors, compared to 76% (95% CI 58-99%) for those with ≥ 3 risk factors. At MVA, the presence of ≥ 3 risk factors was associated with a higher risk of recurrence [hazard ratio: 4.74, 95% CI 1.75-12.8, p = 0.002]. CONCLUSION: Among patients with LG IR-NMIBC eligible for AS, those with more than 2 IBCG risk factors may not be suitable candidates due to a higher risk of developing HG recurrence. Randomized controlled trials with standardized AS protocols are necessary to validate these findings and optimize patient selection for AS in LG IR-NMIBC.	bladder
PICC management for bladder tumor patient with toxic epidermal necrolysis: A crisis intervention case report.	Crisis intervention is crucial in managing acute medical crises to improve outcomes. Toxic Epidermal Necrolysis (TEN), a severe skin reaction often triggered by drug exposure, poses challenges, especially in chemotherapy patients. Evidence on nursing care for TEN patients with Peripherally Inserted Central Catheter (PICC) retention during chemotherapy is limited. We present a 69-year-old male with recurrent bladder tumor receiving atezolizumab via PICC, developing TEN and catheter-associated skin impairment (CASI). Despite extensive skin breakdown, PICC retention was essential and innovative PICC care was necessary. A crisis management team implemented a six-step crisis intervention model, ensuring safety and treatment adherence. A three-layer dressing protocol was used to optimize wound care, prevent further CASI, and ensure the patient's comfort. This case underscores the efficacy of crisis intervention in managing TEN with PICC during chemotherapy, highlighting interdisciplinary collaboration and innovation in complex medical scenarios.	bladder